Cinaciguat prevents neointima formation after arterial injury by decreasing vascular smooth muscle cell migration and proliferation

International Journal of Cardiology

Volumn 167, Issue 2, 2013, Pages 470-477

  Hirschberg, K ^a,b   Tarcea, V ^a   Pali Sz ^a   Barnucz, E ^a,b   Gwanmesia, P N ^a   Korkmaz, S ^a   Radovits, T ^a,b   Loganathan, S ^a   Merkely, B ^b   Karck, M ^a   Szabo G ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Cinaciguat; Injury; Metalloproteinases; Neointima; Restenosis

Indexed keywords

CINACIGUAT; CYCLIC GMP; GELATINASE B; GUANYLATE CYCLASE; GUANYLATE CYCLASE BETA1; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ARTERY OBSTRUCTION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME REGULATION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INHIBITION KINETICS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; TREATMENT DURATION; TREATMENT OUTCOME; UPREGULATION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; WOUND HEALING;

ANIMALS; BENZOATES; CAROTID ARTERY INJURIES; CELL MOVEMENT; CELL PROLIFERATION; GUANYLATE CYCLASE; MALE; MATRIX METALLOPROTEINASE 9; MUSCLE, SMOOTH, VASCULAR; NEOINTIMA; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84879121862     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.01.032     Document Type: Article

References (36)

1. G.D. Dangas, B.E. Claessen, A. Caixeta, E.A. Sanidas, G.S. Mintz, and R. Mehran In-stent restenosis in the drug-eluting stent era J Am Coll Cardiol 56 2010 1897 1907
2. A.K. Hassan, S.C. Bergheanu, and T. Stijnen Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis Eur Heart J 31 2010 1172 1180
3. W.S. Weintraub The pathophysiology and burden of restenosis Am J Cardiol 100 2007 3K 9K
4. V.O. Melichar, D. Behr-Roussel, and U. Zabel Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis Proc Natl Acad Sci USA 101 2004 16671 16676
5. P. Sinnaeve, J.D. Chiche, and H. Gillijns Overexpression of a constitutively active protein kinase G mutant reduces neointima formation and in-stent restenosis Circulation 105 2002 2911 2916
6. P. Sinnaeve, J.D. Chiche, and Z. Nong Soluble guanylate cyclase alpha(1) and beta(1) gene transfer increases NO responsiveness and reduces neointima formation after balloon injury in rats via antiproliferative and antimigratory effects Circ Res 88 2001 103 109
7. K. Hirschberg, T. Radovits, and S. Loganathan Selective phosphodiesterase-5 inhibition reduces neointimal hyperplasia in rat carotid arteries after surgical endarterectomy J Thorac Cardiovasc Surg 137 2009 1508 1514
8. S. Janssens, D. Flaherty, and Z. Nong Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats Circulation 97 1998 1274 1281
9. A.N. Keswani, K.J. Peyton, W. Durante, A.I. Schafer, and D.A. Tulis The cyclic GMP modulators YC-1 and zaprinast reduce vessel remodeling through antiproliferative and proapoptotic effects J Cardiovasc Pharmacol Ther 14 2009 116 124
10. O. Varenne, S. Pislaru, and H. Gillijns Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs Circulation 98 1998 919 926
11. E.J. Tsai, and D.A. Kass Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics Pharmacol Ther 122 2009 216 238
12. D.A. Tulis Novel Therapies for Cyclic GMP Control of Vascular Smooth Muscle Growth Am J Ther 15 2008 551 564
13. O.V. Evgenov, P. Pacher, P.M. Schmidt, G. Hasko, H. Schmidt, and J.P. Stasch NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential Nat Rev Drug Discov 5 2006 755 768
14. J.P. Stasch, E.M. Becker, and C. Alonso-Alija NO-independent regulatory site on soluble guanylate cyclase Nature 410 2001 212 215
15. J.P. Stasch, P. Schmidt, and C. Alonso-Alija NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle Br J Pharmacol 136 2002 773 783
16. S. Hingorany, and W.H. Frishman Soluble guanylate cyclase activation with cinaciguat: a new approach to the treatment of decompensated heart failure Cardiol Rev 19 2011 23 29
17. H. Lapp, V. Mitrovic, and N. Franz Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure Circulation 119 2009 2781 2788
18. R. Dumitrascu, N. Weissmann, and H.A. Ghofrani Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling Circulation 113 2006 286 295
19. V. Lindner, J. Fingerle, and M.A. Reidy Mouse model of arterial injury Circ Res 73 1993 792 796
20. M. Sata, Y. Maejima, and F. Adachi A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by reproducible neointimal hyperplasia J Mol Cell Cardiol 32 2000 2097 2104
21. C.C. Liang, A.Y. Park, and J.L. Guan In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro Nat Protoc 2 2007 329 333
22. J.M. Daniel, W. Bielenberg, P. Stieger, S. Weinert, H. Tillmanns, and D.G. Sedding Time-course analysis on the differentiation of bone marrow-derived progenitor cells into smooth muscle cells during neointima formation Arterioscler Thromb Vasc Biol 30 2010 1890 1896
23. E.B. Jackson, S. Mukhopadhyay, and D.A. Tulis Pharmacologic modulators of soluble guanylate cyclase/cyclic guanosine monophosphate in the vascular system - From bench top to bedside Curr Vasc Pharmacol 5 2007 1 14
24. Y.N. Liu, S.L. Pan, and C.Y. Peng YC-1 [3-(5 '-hydroxymethyl-2 '-furyl)-1-benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metalloproteinases 2 and 9 J Pharmacol Exp Ther 316 2006 35 41
25. D.A. Tulis Bohl Masters KS, Lipke EA, et al. YC-1-mediated vascular protection through inhibition of smooth muscle cell proliferation and platelet function Biochem Biophys Res Commun 291 2002 1014 1021
26. T. Munzel, R. Feil, A. Mulsch, S.M. Lohmann, F. Hofmann, and U. Walter Physiology and pathophysiology of vascular signaling controlled by guanosine 3',5'-cyclic monophosphate-dependent protein kinase [corrected] Circulation 108 2003 2172 2183
27. R. Lukowski, P. Weinmeister, and D. Bernhard Role of smooth muscle cGMP/cGKI signaling in murine vascular restenosis Arterioscler Thromb Vasc Biol 28 2008 1244 1250
28. L.J. Feldman, M. Mazighi, and A. Scheuble Differential expression of matrix metalloproteinases after stent implantation and balloon angioplasty in the hypercholesterolemic rabbit Circulation 103 2001 3117 3122
29. K.E. Webb, A.M. Henney, S. Anglin, S.E. Humphries, and J.R. McEwan Expression of matrix metalloproteinases and their inhibitor TIMP-1 in the rat carotid artery after balloon injury Arterioscler Thromb Vasc Biol 17 1997 1837 1844
30. H. Guo, N. Makarova, and Y. Cheng The early- and late stages in phenotypic modulation of vascular smooth muscle cells: differential roles for lysophosphatidic acid Biochim Biophys Acta 1781 2008 571 581
31. N.N. Mendelev, V.S. Williams, and D.A. Tulis Antigrowth Properties of BAY 41-2272 in Vascular Smooth Muscle Cells J Cardiovasc Pharmacol 53 2009 121 131
32. C.H. Wu, W.C. Chang, G.Y. Chang, S.C. Kuo, and C.M. Teng The inhibitory mechanism of YC-1, a benzyl indazole, on smooth muscle cell proliferation: an in vitro and in vivo study J Pharmacol Sci 94 2004 252 260
33. T. Inoue, and K. Node Molecular basis of restenosis and novel issues of drug-eluting stents Circ J 73 2009 615 621
34. S. Roger, J. Paysant, C. Badier-Commander, A. Cordi, T.J. Verbeuren, and M. Feletou Anti-aggregating effect of BAY 58-2667, an activator of soluble guanylyl cyclase Vascul Pharmacol 53 2010 281 287
35. J.T. Dodge Jr. Brown BG, Bolson EL, Dodge HT. Lumen diameter of normal human coronary arteries. Influence of age, sex, anatomic variation, and left ventricular hypertrophy or dilation Circulation 86 1992 232 246
36. A.G. Touchard, and R.S. Schwartz Preclinical restenosis models: challenges and successes Toxicol Pathol 34 2006 11 18